Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Astellas US LLC has 1 pending office action currently active in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to Dana H. Shin within 1 distinct art unit. The company's current pending workload is focused entirely on this single application. This means that the company's immediate progress in the Biotechnology & Pharmaceuticals sector is dependent on the results of this one specific prosecution. Because there is only 1 pending office action, the portfolio suggests a very narrow or early-stage presence in this particular technology area at the patent office.
Dana H. Shin is the busiest examiner for the company, overseeing the 1 pending office action. With only 1 distinct examiner and 1 distinct art unit involved, the company's immediate prosecution profile is limited to this one interaction. The results of this single pending action will be the primary indicator of the company's current success at the patent office. Practitioners should prioritize understanding the examination style of Dana H. Shin to navigate this 1 pending office action effectively. The lack of additional pending matters means there are no other examiners or art units to consider within the company's current portfolio, placing significant importance on the outcome of this individual case.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIN, DANA H | 1 | 27.0% | +27.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19413886 | PHARMACEUTICAL COMPOSITIONS FOR DELIVERY TO THE EYE | SHIN, DANA H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19413886 | PHARMACEUTICAL COMPOSITIONS FOR DELIVERY TO THE EYE | SHIN, DANA H | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19413886 | PHARMACEUTICAL COMPOSITIONS FOR DELIVERY TO THE EYE | SHIN, DANA H | 1635 | §102§112DP | Non-Final OA | — | Pending | Dec 09, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial